Overexposure to Bisphenol A and Its Chlorinated Derivatives of Patients with End-Stage Renal Disease during Online Hemodiafiltration
Astrid Bacle,
Antoine Dupuis,
Mohamed Belmouaz,
Marc Bauwens,
Guillaume Cambien,
Nicolas Venisse,
Pascale Pierre-Eugene,
Sophie Potin,
Virginie Migeot,
Sarah Ayraud-Thevenot
Affiliations
Astrid Bacle
INSERM, University Hospital of Poitiers, University of Poitiers, CIC1402, 86021 Poitiers CEDEX, France
Antoine Dupuis
INSERM, University Hospital of Poitiers, University of Poitiers, CIC1402, 86021 Poitiers CEDEX, France
Mohamed Belmouaz
Digestiv, Urology, Nephrology, Endocrinology Department, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
Marc Bauwens
Digestiv, Urology, Nephrology, Endocrinology Department, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers CEDEX, France
Guillaume Cambien
INSERM, University Hospital of Poitiers, University of Poitiers, CIC1402, 86021 Poitiers CEDEX, France
Nicolas Venisse
INSERM, University Hospital of Poitiers, University of Poitiers, CIC1402, 86021 Poitiers CEDEX, France
Pascale Pierre-Eugene
Faculty of Medicine and Pharmacy, University of Poitiers, 6 rue de la Milétrie, 86000 Poitiers, France
Sophie Potin
Research Institute for Environmental and Occupational Health (IRSET-INSERM UMR 1085), University of Rennes 1, 2 Avenue du Pr Léon Bernard, 35043 Rennes, France
Virginie Migeot
INSERM, University Hospital of Poitiers, University of Poitiers, CIC1402, 86021 Poitiers CEDEX, France
Sarah Ayraud-Thevenot
INSERM, University Hospital of Poitiers, University of Poitiers, CIC1402, 86021 Poitiers CEDEX, France
The health safety conditions governing the practice of online hemodiafiltration (OL-HDF) do not yet incorporate the risks related to the presence of endocrine disruptors such as bisphenol A (BPA). The aim of this study was to assess, for the first time, the exposure to BPA but also to its chlorinated derivatives (ClxBPA) (100 times more estrogenic than BPA) during OL-HDF. We demonstrated that BPA is transmitted by the different medical devices used in OL-HDF: ultrafilters, dialysis concentrate cartridges (and not only dialyzers, as previously described). Moreover, BPA has been found in dialysis water as well as in ultrapure dialysate and replacement fluid due to contamination of water coming from municipal network. Indeed, due to contaminations provided by both ultrafilters and water, high levels of BPA were determined in the infused replacement fluid (1033 ng.L−1) from the beginning of the session. Thus, our results demonstrate that dialysis water must be considered as an important exposure source to endocrine disruptors, especially since other micropollutants such as ClxBPA have also been detected in dialysis fluids. While assessment of the impact of this exposure remains to be done, these new findings should be taken into account to assess exposure risks in end-stage renal disease patients.
